You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis

Article info

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Scleroderma, myositis and related syndromes
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis

Authors

Citation

Gordon P, Cooper R, Chinoy H, et al
AB0629 Design of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of The Toll-like Receptor Antagonist IMO-8400 in Patients with Dermatomyositis
Annals of the Rheumatic Diseases 2016;75:1119.

Publication history

  • First published July 15, 2016.
Online issue publication 
July 15, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions